Figure 3 | Scientific Reports

Figure 3

From: Dipeptidylpeptidase (DPP)-4 inhibitor therapy increases circulating levels of anti-inflammatory soluble frizzle receptor protein (sFRP)-5 which is decreased in severe COVID-19 disease

Figure 3

Investigation of sFRP5 expression in different cell types of the adipose tissue study cohort: Western blot: sFRP5 expression was analysed in THP-1 control, visceral and subcutaneous adipocytes, pre-adipocytes and macrophages from three representative samples (patient P7, P8, P9). Only visceral and subcutaneous adipocytes showed sFRP5 expression.

Back to article page